Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study
Philippe Moreau(Centre National de la Recherche Scientifique), Jean‐Paul Fermand(Sorbonne Université), Arnaud Jaccard(Centre Hospitalier Universitaire de Limoges), Murielle Roussel(Centre Hospitalier Universitaire de Limoges), Xavier Leleu(Inserm), Olivier Hermine(Centre National de la Recherche Scientifique), Lotfi Benboubker, Bruno Royer(Centre Hospitalier Universitaire Amiens-Picardie), Gilles Salles(Memorial Sloan Kettering Cancer Center), Frank Bridoux(Université de Poitiers), Véronique Leblond(Sorbonne Université), Lucie Planche, Jean‐Luc Harousseau(Institut de Cancérologie de l'Ouest), May Alakl(Goethe University Frankfurt)
Cited by 132
Related Papers
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
|Kidney International|2021|2.5k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis
|American Journal of Hematology|2005|1.4k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k